• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,186.87 1.44
( 0.00%)
Global Indices
Nasdaq
52,569.33 -110.31
(-0.21%)
Dow Jones
7,555.54 -37.86
(-0.50%)
Hang Seng
66,873.37 -1,878.14
(-2.73%)
Nikkei 225
10,555.24 39.32
(0.37%)
Forex
USD-INR
96.14 0.39
(0.40%)
EUR-INR
109.70 0.52
(0.48%)
GBP-INR
128.61 0.54
(0.42%)
JPY-INR
0.59 0.00
(0.41%)

EQUITY - MARKET SCREENER

Nectar Lifescience Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532649
INE023H01027
29.975455
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NECLIFE
0
214.46
EPS(TTM)
Face Value()
Div & Yield %
0
1
0
 

SML Mahindra reports 3% YoY rise in June’26 sales
Jul 01,2026

The company’s cargo vehicle sales decreased 26% YoY to 355 units, while passenger vehicle sales rose 13% YoY to 1,575 units from 1,391 units in the year-ago period.

SML Mahindra (formerly known as SML Isuzu) is primarily engaged in the business of the manufacture and sale of commercial vehicles and their parts.

The company reported a marginal 2.36% year-on-year (YoY) rise in standalone net profit to Rs 54.20 crore for the fourth quarter ended 31st March 2026, compared with Rs 52.95 crore in the corresponding quarter last year. Revenue from operations rose 16.39% YoY to Rs 897.65 crore in the quarter ended 31 March 2026.

The counter slipped 2.07% to Rs 4,010.90 on the BSE.